Figure 1: Design of the phase III IFCT-GFPC 05-02 trial

(NSCLC = non-small cell lung cancer; PS = performance-status; R = randomization; EGFR = epidermal growth factor receptor; IHC = immunohistochemistry; PD = progressive disease)

According to their status at this time, patients then received 2nd line pemetrexed until their second disease progression, followed by palliative care until death. Patients not given second-line therapy directly received best supportive care until death.